SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES

USING UPLC-MS/MS by Tang, Chenxiao
SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES 
USING UPLC-MS/MS 
 
 by 
Chenxiao Tang 
Bachelor of Science, Capital Medical University, 2014 
Submitted to the Graduate Faculty of 
School of Pharmacy in partial fulfillment  
of the requirements for the degree of 
Master of Science 
University of Pittsburgh 
2016 
  ii 
 
 
 
 
 
 
 
 
 
Copyright © by Chenxiao Tang 
2016 
 
 
 
 
 
 
 
  iii 
SCREENING 20-HETE INHIBITORS IN MICROSOMAL INCUBATES USING  
UPLC-MS/MS 
 Chenxiao Tang, B.S.  
University of Pittsburgh, 2016 
20-hydroxyeicosatetraenoic acid (20-HETE) is a metabolite of arachidonic acid (AA) 
formed by cytochrome P450 (CYP) 4A11 and CYP4F2 in humans, with potent microvascular 
constriction activity. Inhibition of 20-HETE formation is neuroprotective in subarachnoid 
hemorrhage, cardiac arrest and thromboembolic stroke preclinical models. These findings 
suggest that inhibition of 20-HETE formation is a potential therapeutic strategy for 
neuroprotection after brain injury. At this point, a clinically relevant 20-HETE inhibitor is not 
available to be evaluated as a therapeutic intervention. Our goal is to identify a selective, 
metabolically stable, and potent 20-HETE inhibitor. Test compounds were obtained either via 
virtual screening against a CYP4F2 homology model or from scaffold hopping from structures of 
known inhibitors. Four different types of microsomes including human liver microsome (HLM), 
recombinant CYP4F2 (rCYP4F2), rat liver microsome (RLM) and rat kidney microsome (RKM) 
were used. AA was incubated in microsomes with/without compound for 20 min. 20-HETE 
formation rate was quantified using a validated UPLC-MS/MS assay and normalized by vehicle 
control group. Other eicosanoids including 15-, 12-HETEs, epoxyeicosatrienoic acids (EETs), 
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and dihydroxyeicosatrienoic acids (DiHETs) were monitored simultaneously. Selected 
compounds were tested in HLM for metabolic stability over 60 minutes. Remaining amount of 
compound was quantified using UPLC-MS/MS and normalized to corresponding 0-min values. 
Among 26 compounds, compounds 10 and 26 both inhibited 20-HETE formation in a dose-
dependent manner. At 2500nM, compound 10 reduced 20-HETE formation to 19.9±1.8%, 
24.0±5.5% in rCYP4F2 and HLM compared with control; compound 26 decreased 20-HETE 
formation to 32.4±6.5%, 34.8±5.1% in rCYP4F2 and HLM, respectively. After structure 
modification, compound 19 and its hydrochloride salt compound 18 were the most potent and 
dose-dependently inhibited 20-HETE formation. At 2500nM, compound 19 decreased 20-HETE 
formation to 4.4±0.4%, 8.6±1.3% in rCYP4F2 and HLM, respectively without inhibitory effects 
on 15-, 12-HETE, EETs or DiHETS formation. Compounds 10 and 19 were more stable with 
91.4±11.0% and 100.4±1.7% remaining compound at 30min in HLM compared to 35.1±5.7% of 
3-(4-n-butoxyphenyl)pyrazole. These results suggested that compounds 10, 19 and 26 are potent 
20-HETE formation inhibitors, compounds 10 and 19 have improved microsomal stability, and 
these three compounds can serve as lead compounds for further structure modifications that may 
lead to novel 20-HETE formation inhibitors. 
Key words: 20-hydroxyeicosatetraenoic acid; epoxyeicosatrienoic acid; UPLC-MS/MS; 
microsome incubation; inhibitor 
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1.0  INTRODUCTION 
 
1.1 BRAIN INJURY IN CEREBROVASCULAR AND CARDIOVASCULAR DISEASES 
 
1.1.1 Stroke 
 
Stroke is the fifth leading cause of death in the US. Each year, approximately 795,000 people 
experience a new or recurrent stroke [1]. There are two types of strokes: ischemic stroke and 
hemorrhagic stroke. Ischemic strokes are caused by obstruction within a blood vessel that 
supplies blood to the brain. It accounts for 87% of all strokes [1]. Hemorrhagic strokes are less 
common, accounting for 13% of all stroke cases [1]. There are two types of hemorrhagic strokes 
based on location: intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), taking 
up 10% and 3% of all strokes, respectively [1]. ICH happens when diseased blood vessels burst 
and blood leaks into brain parenchyma or the surrounding meningeal spaces. SAH refers to 
bleeding into the subarachnoid space between the pial and arachnoid membranes. According to 
the American Heart Association/American Stroke Association (AHA/ASA) website, strokes 
caused by unknown factors are categorized as cryptogenic stroke. Transient ischemic attack (TIA) 
is a transient episode of neurologic dysfunction caused by ischemia in focal brain, spinal cord, or 
retinal, without acute infarction. TIA symptoms occur rapidly and last for a short time, usually 
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less than an hour. Patients with untreated TIA have a 10% chance of developing a stroke in the 
next 7 days [1]. 
 
1.1.1.1 Ischemic Stroke:  Ischemic strokes are divided into two types: thrombotic stroke and 
embolic stroke. In thrombotic stroke, a blood clot is formed in an artery that supplies blood to the 
brain. In an embolic stroke, a blood clot or other substances travel through the bloodstream to an 
artery in the brain. Despite different types of ischemic stroke, oxygen-rich vascular supply is 
compromised. Ischemia causes brain damage by oxygen or glucose depletion, energy failure and 
disturbance of subsequent energy-dependent processes. The extent of brain injury depends on the 
severity, duration and location of ischemia [2]. Depletion of cellular energy causes imbalance in 
ion pumps. Elevation of intracellular Na
+
, Ca
2+
 and extracellular K
+
 will cause cytotoxic edema 
[3]. With energy depletion, an excitotoxic amino acid, glutamate, is released, activating of 
glutamate receptors which leads to Na
+
, Ca
2+
 influx, thus exacerbating edema and toxicity [3]. 
Generation of oxygen-free radicals and reactive oxygen species can react with cellular 
components and trigger inflammation and apoptotic pathways [2]. Apoptosis is an energy 
consuming process, so restoration of blood flow could potentiate apoptosis [3]. Inflammation 
molecules, free radicals, hypoxia damage and destruction of basal lamina by matrix 
metalloproteinases could cause disruption of the blood brain barrier (BBB) [3]. There is 
increased angiogenesis in ischemic stroke within penumbra in humans. Rodent studies 
demonstrated the increased expression of mRNA of angiogenesis genes and angiogenic protein 
in ischemic area, however, it is still unclear if angiogenesis response could lead to development 
of functional new blood vessels and improve brain function after ischemic stroke [4]. 
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The inner core of the cerebral vascular tissue that undergoes ischemia is hypoperfused 
(18–20 ml/100 g/min) and is at risk of dying within hours whereas penumbra perfused at 60 
ml/100 g/min is less likely to die [2]. Early restoration of blood flow by pharmacological 
intervention or mechanical recanalization could salvage neurons and glia cells from the inner 
core as well as penumbra and reduce infarct size. However, some patients experienced 
reperfusion injury, fatal edema and intracranial hemorrhage, after reperfusion [5]. After 
reperfusion, reactive hyperemia occurs where there is an elevation of regional blood flow along 
with loss of cerebral autoregulation and increased BBB permeability [6]. Following postischemic 
hyperperfusion, a secondary hypoperfusion phase occurs, which lasts for 18 to 96 hours resulting 
in cerebral metabolic depression, microvascular obstruction, occlusion via swelling of 
endothelial cells and astrocytic end-feet, and formation of endothelial microvilli. All these 
contribute to increased paracellular permeability, which is associated with vasogenic edema that 
worsens reperfusion injury. Hillis et al. reported that reduction in volume of hypoperfused brain 
regions is a marker of response to treatment to improve perfusion [7]. Recombinant tissue-type 
plasminogen activator (rt-PA) is the only drug FDA approved for treating ischemic stroke 
patients via its antithrombotic effect [8]. Unfortunately, rt-PA may cause symptomatic 
intracranial hemorrhage and should be intravenously administered within three hours after stroke 
symptoms onset to achieve its benefits [9, 10]. 
 
1.1.1.2 Subarachnoid Hemorrhage:  Eighty percent of subarachnoid hemorrhage occurs due to 
bleeding from cerebral aneurysm and ten percent occurs due to rupture of arteriovenous 
malformation. Rupture of mycotic aneurysm, angioma, neoplasm and cortical thrombosis are the 
other remaining causes of SAH. Approximately 30,000 people experience an aneurysmal 
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subarachnoid hemorrhage (aSAH) each year [11]. aSAH is associated with a significant case 
fatility ranging from 8% to 67% and significant morbidity among survivors [12, 13].  
Early brain injury (EBI) is an emerging cause of morbidity and mortality after SAH. The 
definition of EBI is the immediate injury to the brain within the first 72 hours of the ictus, 
secondary to SAH [14]. EBI refers to the complications that happen before vasospasm and 
delayed cerebral ischemia (DCI) [15]. During aneurysmal rupture, intracranial pressure (ICP) 
increases. Possible mechanisms of ICP elevation include volume increase secondary to SAH, 
vasoparalysis and cerebral spinal fluid (CSF) drainage obstruction [15]. If bleeding continues 
and ICP remains elevated, it could induce a decrease in cerebral perfusion pressure (CPP), 
decrease in cerebral blood flow (CBF), as CPP=MAP-ICP and CBF=CPP/coronory vasucular 
resistance (CVR), and cerebral ischemia and patients could die immediately [15]. Cellular 
apoptosis can be activated by the increase in ICP. Neuronal apoptosis has been shown in the 
hippocampus and cortex in humans [16]. Apoptosis has also been linked to the development of 
vasospasm [15]. Prolonged and ICP-independent hypoperfusion was found in the acute phase 
after SAH clinically and experimentally, indicating acute vasospasm [17].  
Vasospasm and delayed cerebral ischemia (DCI) that happen 3-14 days after initial 
hemorrhage remain to be the common causes of increased morbidity [11]. Approximately 70% 
of patients develop cerebral vasospasm after aSAH [18]. Cerebral vasospasm describes the 
narrowing of cerebral arteries that can be detected by angiography or sonography [11]. 
Vasospasm usually has an onset at 3 days after SAH, reaches maximum constriction on 5 to 14 
days and gradually resolves at 2 to 4 weeks [11]. While cerebral vasospasm has been found to be 
associated with the reduction in CBF in various studies, it is also associated with reduction in 
cerebral perfusion but not regional perfusion. This association is supported by the fact that 
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hypoperfusion was seen in 46 regions but 66% of these were supplied by vessels with no 
significant vasospasm and some patients without vasospasm still could have hypoperfused 
regions in a SAH corhort study [19]. DCI happens in about 30% of aSAH patients [11]. DCI is 
defined as the presence of focal neurological deficit or a decrease in the Glasgow Coma Scale of 
at least two points with an disturbance in cerebral blood flow [20]. It has long been implicated 
that cerebral vasospasm plays a causative role in developing DCI. However, clinical trials 
showed that clazosentan treatment didn’t significantly reduce delayed ischemic neurological 
deficit while showing reduction in moderate or severe vasospasm [21]. Similarly, one parallel 
study found that delayed cerebral infarction could develop in brain regions without vasospasm 
and it accounts for >25% of infarct from DCI [22]. These indicated an association instead of a 
causal relationship between cerebral vasospasm and DCI, other processes that happen in a 
microvascular level could attribute to part of the burden from DCI [22].  
Prophylactic oral nimodipine and initiation of triple-H therapy have the strongest 
evidence in treating vasospasm [23]. Triple-H therapy increases cerebral blood flow by 
increments of intravascular volume and reduction of blood viscosity, but failed to show 
improvement in delayed neurological deficits or clinical outcome [23]. Nimodipine is a calcium 
channel blocker indicated for improving neurological outcomes after SAH. In a British 
Aneurysm Nimodipine Trial, patients who had oral nimodipine demonstrated a 34% reduction in 
cerebral infarction and a 40% reduction in poor outcome at three months. 
 
1.1.2 Cardiac Arrest 
 
Cardiac arrest is defined as the cessation of cardiac mechanical activity and confirmed by the 
absence of signs of circulation. In 2014, 6328 children (<18 years) and 320157 adults 
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experienced out-of hospital cardiac arrest and survival to hospital discharge was only around 7-
10% [24]. Whole-body ischemia during cardiac arrest and after return of spontaneous circulation 
(ROSC) lead to a series of post-cardiac arrest syndrome, including post-cardiac arrest brain 
injury, post-cardiac arrest myocardial injury, systemic ischemia/reperfusion response and 
persistent precipitating pathology. Brain, particularly cerebral cortex, is vulnerable to 
ischemic/reperfusion injury and post-resuscitation neurological dysfunction of cardiac arrest 
represents the major cause of mortality and morbidity [25]. Upon cessation of cerebral 
circulation, oxygen is depleted, followed by energy depletion. Inability to maintain Ca
2+
 
homeostasis could result in the release of free fatty acid, mainly arachidonic acid, and induce 
vasospasm. Free radical formation and activation of protease cascades lead to damage in 
membrane structure, DNA and mitochondria. Activation of cell-death signaling pathways and 
excitotoxicity during ischemia and after reperfusion of cardiac arrest all contribute to post-
cardiac arrest brain injury [25-27].  
Animal studies show that there is a short period of multifocal no-reflow right after 
resuscitation from cardiac arrest. This is followed by a 15-30 min transient global hyperemia that 
causes impaired cerebral autoregulation. While the cerebral metabolic fate gradually recovers, 
cerebral blood flow is severely reduced for 2-12 hours, which is called the delayed 
hypoperfusion phase. After restoration of CBF and metabolism, there might be secondary 
hyperemia [25, 28]. The prolonged phase of hypoperfusion is correlated to neurocognitive, 
behavioral, sensory and motor function deficit and may represent a therapeutic target for 
ischemic/reperfusion injury [16]. For example, simultaneous chest compression cardiopulmonary 
resuscitation (CPR) combined with abdominal binding improves cerebral perfusion by elevating 
cerebral perfusion pressure in dog after cardiac arrest [29]. In a ventricular fibrillation cardiac 
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arrest (VFCA) model in pig, the endothelin-1 treated group showed dose-dependent elevation in 
CBF after resuscitation from VFCA and increased resuscitation success [30]. On the contrary, 
BQ123, an antagonist of endothelin type A receptor, reversed cerebral hypoperfusion and 
improved functional outcome in cardiac arrest rats [31].   
One important treatment to prevent secondary brain injury and improve neurological 
outcome is the application of therapeutic hypothermia. Preclinical research showed hypothermia 
improved functional, neurological and morphological cerebral outcome in dogs and rats [32-35]. 
Clinical evidence showed that 49% of the patients treated with hypothermia (33°C) had a good 
outcome compared to 26% in the normothermia group, with an odds ratio of 5.25 [36]. Based on 
the published evidence, AHA recommended therapeutic hypothermia as standard of care in 
patients after resuscitation from VFCA. In 2009, an international conference provided consensus 
recommendations to targeted temperature management in critical care, where “therapeutic 
hypothermia” was recommended to replace by “targeted temperature management” and targeted 
temperature management profile should be explicitly indicated instead of using “mild”. 
Recommendations also include 32-34°C as preferred treatment for out-of-hospital cardiac arrest 
adult patients with ventricular fibrillation or pulseless ventricular tachycardia and still 
unconscious after restoration of spontaneous circulation [37]. Possible protective mechanisms of 
hypothermia include: (1) a 6% reduction in cerebral metabolic rate for oxygen when every 1°C 
reduction in brain temperature; (2) suppression of free radical production, excitatory amino acid 
release, and calcium shifts that are associated with hyperthermia; (3) attenuation of pro-apoptosis 
signals; (4) upregulation of p53 that promote repair after focal ischemia and (5) reduction in a 
neuron death marker enolase [38].  
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Collectively, cardiac arrest, ischemic stroke and subarachnoid hemorrhage share common 
mechanisms in pathophysiology of brain injury. Cerebral hypoperfusion is one common 
mechanism that contributes to secondary brain injury and may serve as a potential treatment 
target in cardiovascular and cerebrovascular diseases. 20-HETE as microvascular constrictor 
could also regulate CBF through alteration of CVR. The following section will introduce 20-
HETE production and its biological effects.  
 
 
1.2 ARACHIDONIC ACID METABOLISM PATHWAY AND EICOSANOIDS 
BIOLOGICAL EFFECTS 
 
1.2.1 Arachidonic Acid Metabolism Pathway 
 
Arachidonic acid (AA) is a polyunsaturated ω-6 fatty acid that is esterified in the cell membrane. 
It can be activated by cytosolic phospholipid A2 (cPLA2) under different stimuli to release free 
AA for oxidized metabolism [39]. Once released, free AA is metabolized by three enzymatic 
pathways, including cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 
(CYP450) [40]. COX catalyze AA into prostaglandins PGG2 and PGH2, which are further 
converted into vasodilatory prostaglandins PGE2, PGF2α, prostacyclins PGI2 and thromboxanes 
TXA2 and TXB2 [41]. Several different LOX, 5-, 12-, and 15-LOX metabolize AA into 5-, 12-, 
15-HETE, which are converted to leukotrienes and lipoxins [41]. CYP450 pathways metabolize 
AA by hydroxylation, olefin epoxidation and bis-allylic oxidation into hydroxyeicosatetraenoic 
acids (HETEs) and epoxyeicosatrienoic acids (EETs). AA ω-/ω-1 hydroxylation happens at or 
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near the terminal carbon and yields 16-, 17-, 18-, 19-, 20-HETE [42]. Bis-allylic oxidation 
generates 5-, 8-, 9-, 11-, 12-, 13-, and 15-HETE [42, 43]. Olefin oxidation provides four EETs: 
5,6-, 8,9-, 11,12-, and 14,15-EET [42]. A study done in a group of human recombinant enzymes 
showed that CYP2C19 had the highest catalytic activity (32 pmol/ pmol P450/ min) to 
metabolize AA, followed by CYP1A1, 4F3B, 4A11 and 4F2 [44]. Figure 1 depicts three 
pathways of AA metabolism.  
 
 
Figure 1. Arachidonic acid metabolism pathway 
 
1.2.2 Hydroxylase Pathway and 20-HETE Biological Function 
 
CYP450 hydroxylase pathway regulates formation of 16-, 17-, 18-, 19-, and 20-HETE [42]. 20-
HETE is the major metabolite of AA in various organs such as liver, kidney, heart, lung and 
cerebral arteries [40, 45, 46]. CYP4A and 4F subfamilies are responsible for ω-hydroxylation of 
AA to form 20-HETE [40]. Powell et al. showed that CYP4A11, 4F2 produced 20-HETE in 
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human liver and kidney microsomes, and Lasker et al. demonstrated that CYP4F2 was 
responsible for predominant 20-HETE formation in human kidney [47, 48]. Incubation with 
human recombinant CYP4F3B exhibited high catalytic hydroxylation of AA, and AA ω-
hydroxylated metabolites formed by CYP4F3B decreased to 8% when DHA (50 μM) was 
present, which indicates CYP4F3B is an isoform that could also form 20-HETE [49, 50]. A non-
CYP4 isoform CYP2U1, localized in human brain tissue, also converted AA into 19-HETE and 
20-HETE [51]. In rat, CYP4A1, 4A2, 4A3, 4A8, 4F1, 4F4 has been shown to generate 20-HETE 
and CYP4A2 is considered the major isoform for 20-HETE formation [52-56]. 20-HETE has 
potent microvascular constriction effects, constricting renal, cerebral, mesenteric and skeleton 
muscle arterioles [40]. 20-HETE inhibits large conductance Ca
2+
-activated K
+
 (KCa) channels, 
leading to depolarization of membrane potential and vasoconstriction [57]. 20-HETE is also 
involved in myogenic response in renal, cerebral, mesenteric and skeleton muscle, autoregulation 
of renal and cerebral blood flow, ischemia-induced angiogenesis and PPAR-mediated 
inflammation [57-60].   
 
1.2.3 Epoxygenase Pathway and EETs Biological Function 
 
CYP450 epoxygenase pathway generates four EETs: 5,6-EET, 8,9-EET, 11,12-EET and 14,15-
EET [61]. In general, CYP1A, 2B, 2C, 2D, 2G, 2J, 2N can generate these metabolites from AA 
[39, 62]. In livers and kidneys of both humans and rats, CYP2C8, 2C9 are the major isoforms for 
EETs formation [39]. CYP2J2 is the predominant isoform for EETs formation in human and rat 
heart [63]. Once formed, the majority of EETs are esterified to cellular glycerophospholipids 
[39]. EETs can be metabolized by soluble epoxide hydrolase (sEH) localized in liver, kidney, 
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and brain into corresponding DiHETs [39, 64]. DiHETs are generally viewed as biologically 
inactive or less effective compared with EETs [39, 65]. Other metabolism pathways of EETs 
include β-oxidation, CYP metabolism and glutathione conjugation. On the contrary to 20-HETE, 
EETs dilate kidney, cerebral, mesenteric and pulmonary arterioles, inhibit T-type calcium 
channels, and activate large conductance Ca
2+
-activated K
+
 (KCa) channels, leading to 
hyperpolarization of membrane potential and vasodilation [40, 65, 66]. EETs have anti-
inflammatory effects and inhibit platelet aggregation [40]. EETs also stimulate angiogenesis by 
involving MAPK, P13-k/Akt signaling pathway and eNOS pathway [67].  
 
1.2.4 CYP450 Enzymes and Eicosanoids in Brain 
 
CYP2C, 2D, 2J, 4A, 4F subfamilies are expressed in brain [40, 68, 69]. 20-HETE and EETs are 
formed when incubated with AA in rat cerebral arteriole microsomes and can be found in human 
CSF [58, 70]. 20-HETE is produced in vascular smooth muscle cells, vascular endothelium and 
astrocytes, while EETs are produced in neurons, astrocytes and endothelial cells [40, 71, 72]. 
sEH that bioinactivate EETs is expressed in smooth muscles of the arterioles, neuronal cell 
bodies, oligodendrocytes, and astrocytes [73]. As discussed above, 20-HETE and EETs have 
opposite effects on cerebral arteries. 20-HETE constricts cerebral arteries by activating PKC, Ras, 
tyrosine kinase, MAP and rho kinase pathways, depolarize cell membrane by blocking Kca 
channels, and activating L-type Ca
2+
 channels [74]. 20-HETE and EETs regulate basal blood 
flow in cerebral microcirculation. Subdural administration of CYP450 epoxygenase inhibitor 
miconazole induced a 29.7% decrease in basal blood flow [75]. At 10
-6
 mol/L, 20-HETE 
decreased basal cerebral arteries diameters by 25.3% [58]. 20-HETE has a potential role in CBF 
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autoregulation and this is supported by the evidence that 20-HETE concentration levels increased 
six times as transmural pressure elevated from 20 to 140 mm Hg and in vivo inhibition of 20-
HETE alleviated autoregulation of CBF to elevation of arterial pressure [58]. EETs dilate 
cerebral arteries by activating Kca channels and hyperpolarize cell membranes. 5,6-EET and 
14,15-EET were identified when blood-free mouse brain slices were incubated with exogenous 
radiolabeled AA [76]. Topical application of brain-synthesized 5,6-EET or synthetic 8,9-EET (5 
μg/ml) showed a 28% and 8% dilation in cerebral arteriolar, respectively [76]. Co-localization of 
CYP2C11 and sEH at extrinsic parasympathetic and sensory vasodilator fibers suggested that 
EETs have a role in neurogenic control of cerebral arteries [77]. EETs have also been 
demonstrated to be key mediators in neurovascular coupling [64].  
 
 
1.3 PRECLINICAL AND CLINICAL STUDIES OF EICOSANOIDS IN 
CEREBROVASULAR AND CARDIOVASCULAR DISEASES 
 
Multiple animal and clinical studies have demonstrated that upregulation of 20-HETE is 
detrimental, whereas inhibition of 20-HETE produces protective effects in CA, SAH and 
ischemic stroke.   
 
1.3.1 Eicosanoids in SAH 
 
A number of studies have investigated the role of 20-HETE and EETs in SAH. Various studies 
proved that inhibition of 20-HETE had beneficial effects in CBF and neurological outcomes. 
  13 
Kehl et al. showed that 20-HETE levels drastically increased from 12 to 199 ng/ml in vehicle-
treated rat after SAH [78]. Rats pretreated with N-hydroxy-N-(4-butyl-2-methylphenyl) 
formamidine  (HET0016 10mg/kg i.v.), a 20-HETE formation inhibitor, significantly reduced the 
initial fall in CBF at 10 min after induction of SAH [78]. Pretreatment of N-(3-chloro-4-
morpholin-4-yl) phenyl-N′-hydroxyimido formamide (TS-011 0.01–0.1 mg/kg i.v.), another 20-
HETE formation inhibitor, prevented sustained fall in CBF in rat after induction of SAH [78, 79]. 
In a dual-hemorrhage model of SAH in rat, rats that received TS-011 (0.1 mg/kg i.v.) showed 
recovery of cerebral artery diameter, CBF returned to control values, and reversion of delayed 
vasospasm [80]. Eicosanoids can be found in human CSF as well [70, 81]. Our laboratory found 
in aSAH patients CSF 20-HETE concentrations was associated with delayed cerebral ischemia 
(DCI) and Hunt & Hess score, which represents severity of hemorrhage [82]. This is the first 
clinical evidence that supports an association between 20-HETE CSF levels with poorer aSAH 
outcome. Along with the increase of 20-HETE, CSF levels of the protective vasodilator 14,15-
EET also increased in aSAH patients who experienced DCI [83]. Our laboratory also found that 
aSAH patients with moderate or high 20-HETE CSF concentrations were more likely to have 
unfavorable 3 and 12-months Modified Rankin Scale, quicker onset to develop clinical 
neurologic deterioration and three-fold higher 3 and 12-month mortality [84].  
Decreasing EETs bioinactivation through sEH gene deletion is another strategy to 
produce protective effects after SAH. The most common genetic variants for EPHX2, a gene that 
regulates sEH transcription, are K55R and R287Q. K55R variant confers the increase of sEH 
activity and lowers EETs levels, while R287Q variant leads to a decrease in sEH activity and 
higher EETs levels. aSAH patients with K55R variants had higher odds of new stroke, higher 
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mortality, and worse ICU discharge [85]. In sEH knockout mice, cerebral edema and vascular 
inflammation was less, and behavioral outcome was better compared with wild type mice [86].  
 
1.3.2 Eicosanoids in Ischemic Stroke 
 
Multiple studies in ischemic stroke models established that an increase in 20-HETE is 
deleterious, and an increase in EETs is favorable. Direct infusion of 20-HETE (8 mg/kg or 12 
mg/kg) into carotid artery induced severe neurological deficit and large cortical infarcts that 
resembled the infarct in transient ischemic stroke model in rat [79]. After temporal focal 
ischemia in rats, HET0016 (10 mg/kg i.p.) administration is associated with 79.6% reduction in 
20-HETE levels in brain cortical tissue [87]. HET0016 treated group exhibited reduced lesion 
volume and attenuation of decreased CBF [87]. Similarly, in ischemic stroke rat model, brain 20-
HETE levels significantly increased within 5.5 h after transient middle cerebral artery occlusion 
(MCAO) [88]. Treatment with TS-011 (0.3 mg/kg) led to smaller infarct volume, and improved 
neurological and functional outcome compared with vehicle treatment [88]. 20-HETE is found in 
plasma of ischemic stroke patients, and is associated with unfavorable outcome. In acute 
ischemic stroke patients, plasma 20-HETE as well as EETs, DiHETs, and F2-isoprostane levels 
significantly increased compared with healthy controls, and 20-HETE and EETs levels 
attenuated at 30 days post ischemic stroke [89]. 20-HETE concentrations are associated with 
greater neurological impairment, reduced modified barthel index (MBI), and reduced cognitive 
function. 
Increasing EETs by inhibiting sEH is another strategy to produce protective effect after 
ischemic stroke. Acute inhibition of sEH by trans-4-[4-(3-adamantan-1-yl-ureido)-
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cyclohexyloxy]-benzoic acid (t-AUCB) increased EETs to DiHETs ratio by two fold in rat brain 
cortex [90]. t-AUCB reduced cortical infarct volume by 35%, decreased neuronal cell death and 
improved functional outcome [90]. sEH knock-out reproductively senescent  female mice 
subjected to MCAO showed decreased infarct size and increased cerebral perfusion at 24 h after 
MCAO [91]. Interestingly, therapeutic ultrasound has shown beneficial effect in stroke patients 
by ultrasound-mediated thrombolysis through augmenting vasodilator eicosanoids 8,9-EET, 
11,12-EET, 14,15-EET by more than two fold [92].   
 
1.3.3 Eicosanoids in Cardiac Arrest 
 
20-HETE and EETs disturbance were also found in CA. In an asphyxia cardiac arrest model 
performed in our laboratory, 16-18 day old pediatric rats underwent 9 min /12 min (moderate 
/severe) cardiac arrest. After moderate cardiac arrest, 8,9-EET and 14,15-EET significantly 
increased in cortex and subcortical region. After severe cardiac arrest, 20-HETE significantly 
increased in cortex and subcortical regions [93]. HET0016 (0.9 mg/kg i.v.) administration 
inhibited 20-HETE formation, improved cortical perfusion, decreased neurological deficit score 
(NDS), reduced pyknotic neurons, and percentage of brain tissue water [93]. This suggests that 
inhibition of 20-HETE improves CBF and reduces neurodegeneration. Early administration of 
HET0016 (1 mg/kg) plus delayed therapeutic hypothermia (34°C) in neonatal piglets after 
hypoxia-ischemia enhanced the benefit of delayed therapeutic hypothermia in neuron protection, 
HET0016 plus delayed therapeutic hypothermia treated group showed increase in viable neurons 
in putamen, somatosensory cortex and ventral posterolateral nucleus thalamus [94].  
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There is inconsistency regarding the protective effects of sEH pharmacological inhibition 
or gene deletion. Hutchens et al. showed that sEH gene deletion mice subjected to 10 min CA 
had significantly lower survival rate than wild type mice at 10 min and 24 h after CA and they 
required significantly longer CPR time and more epinephrine [95]. Other studies supported the 
favorable effect of sEH gene deletion or pharmacological inhibition. For example, sEH inhibition 
by 4-phenylchalcone oxide (4-PCO) in mouse CA/CPR model had reduced neuronal cell death 
and improved memory function by inducing anti-inflammatory and neuroprotective IL-
10 expression [96]. 
Together, these studies suggest that reducing 20-HETE production may serve as a 
potential therapeutic strategy in cerebrovascular and cardiovascular diseases. Inhibiting 20-
HETE formation or blocking 20-HETE action can diminish vasoconstriction thus increasing 
cerebral blood flow and produce beneficial neurological outcome.  
 
 
1.4 20-HETE FORMATION INHIBITORS AND ANTAGONISTS 
 
According to the AHA/ASA stroke guidelines, blood pressure management for ischemic stroke 
treatment is a class I recommendation, where treating peri-infarct penumbra characterized with 
impaired cerebral blood flow is dependent on mean arterial blood pressure [8, 97]. The only drug 
that is FDA approved for ischemic stroke treatment is recombinant tissue-type plasminogen 
activator (rt-PA) to dissolve clots and restore cerebral blood flow [8]. Unfortunately, rt-PA may 
cause symptomatic intracranial hemorrhage and must be administered early after strokes [9]. For 
aSAH patients, antifibrinolytic treatment following prophylaxis against vasospasm is 
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recommended by AHA/ASA aSAH guidelines to reduce the threat of ischemic neuronal damage 
through controlling intracranial pressure, decreasing the metabolic rate of oxygen use, and 
improving CBF [98]. However, few therapeutic treatments exist for SAH-induced brain injury 
[98]. In 2010 CA guidelines, neurocritical care was emphasized for post-cardiac arrest patients. 
Few neuroprotective drugs have been tested in clinical trials and no pharmacological agents were 
observed to have neuropretective effect [59]. Thus, intervention treatment for post-injury 
cerebral hypoperfusion and CBF disturbance is inadequate. Emerging evidence of 20-HETE as 
pathogenesis in various neurovascular diseases and its association with unfavorable outcomes 
has made it a potential treatment target in ischemic stroke, SAH and CA.  
 
1.4.1 20-HETE Formation Inhibitors 
 
There has been a wealth of compounds synthesized to either target enzymes that are responsible 
for 20-HETE formation or act as antagonists of 20-HETE to block its effects. Table 1 is a 
summary of IC50 values and inhibition mechanisms of 20-HETE inhibitors and antagonists [99]. 
Several compounds inhibit 20-HETE and EETS formation nonselectively. β-diethyl-
aminoethyldiphenylpropylacetate (SKF-525A) nonselectively inhibits EETs and 20-HETE 
formation by binding to the heme in CYP enzymes and reduces availability of the heme to 
incorporate into CYP enzymes [40, 100]. 17-octadecynoic acid (17-ODYA) is a fatty acid 
analogue, which inhibits 20-HETE formation avidly depending on the terminal acetylenic moiety 
[101]. However, it also inhibits epoxygenases effectively at the same concentration [102]. 
Compound 1-aminobenzotriazole (ABT) (50 mg/kg) administered intraperitonealy completely 
inhibited 20-HETE and EETs formation, it disrupts CYP450 function by binding a benzene 
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group to the heme [103, 104]. In addition to these compounds, endogenous vasodilators, nitric 
oxide (NO) and carbon monoxide (CO), bind to the heme in the CYP enzymes and block 20-
HETE and EETs formation simultaneously even though NO donor dose-dependently inhibited 
20-HETE formation in renal microsomes [105]. 
Selective 20-HETE formation inhibitors were developed to specifically target the 
hydroxylase pathway, while minimizing the effects on the epoxygenase pathway. N-
methylsulfonyl-12,12-dibromododec-11-enamide (DDMS) and 12-12-dibromododec-11-enoic 
acid (DBDD) are dibromoolefinic fatty acids [106]. In rat renal cortical microsomes, DDMS and 
DBDD inhibited ω-hydroxylation of AA with IC50 of 2 μM and there was about a 20% reduction 
in EETs at 10 μM. As concentration increases, DDMS and DBDD inhibit the epoxygenase 
pathway with an IC50 of 60 μM and 51 μM, respectively [106]. One-hour intravenous infusion of 
DDMS (10 mg/kg) reduced rat renal 20-HETE formation by 70% [107]. Because DDMS and 
DBDD are fatty acids, in vivo application might be restrained due to protein binding [40]. 
HET0016 is a selective, potent 20-HETE formation inhibitor in both humans and rats. It inhibits 
20-HETE in a dose-dependent manner with an IC50 value of 35.2±4.4 nM and 8.9±2.7 nM in rat 
and human renal microsomes, respectively [108]. EETs inhibition occurs at IC50 (2800±300 nM) 
100 times higher [108]. However, HET0016 is plagued by low water solubility (3.7 μg/ml), short 
half-life (39.6±20.0 min) and instability under acidic environment (43.2% remaining) [109, 110]. 
Several pyrazole and isoxazole derivatives of HET0016 showed selective inhibition against 20-
HETE formation with better stability and solubility profile, such as 3-(4-n-
Butoxyphenyl)pyrazole [110]. N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido 
formamide (TS-011) is a newer selective, potent 20-HETE formation inhibitor with a IC50 range 
of 10-50 nM in human renal microsomes and recombinant CYP4A11, 4F2, 4F3B against 20-
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HETE formation and has little effect against other CYP450 isoforms [79]. Unfortunately, TS-011 
has a shockingly short half-life of 10 min when i.v. injected in rat and its main metabolite did not 
show inhibitory effects against 20-HETE formation in human renal microsomes [79]. 
Several clinically approved drugs and supplements have demonstrated inhibitory effects 
against 20-HETE formation. Fluoxetine has been proven to have protective effects by preventing 
BBB disruption in global ischemia-induced neuronal death [111]. In a study done in neonatal rats, 
transient postnatal fluoxetine (10 mg/kg) exposure reduced brain 20-HETE concentration by 
70.3%, indicating that fluoxetine may be a potential therapeutic agent in ischemic brain injury 
patients [112].  Isoniazid inhibited 20-HETE levels in rat liver and kidney tissue by 34±10% and 
15.6±5.3% of control, respectively [113]. Cardiac hypertrophy-induced rats treated with 
isoniazid (200mg/kg/day) showed increased cardiac 19-HETE levels by 20-fold and significant 
reduced 20-HETE levels by 98% [114]. By Monte Carlo simulations, El-Sherbeni et al. predicted 
that 2.5g daily high and safe oral resveratrol will decrease 20-HETE levels by 16-35% in 90% of 
human population [44]. Sesamin and sesamolin are plant lignans derived from sesame, which 
inhibited 20-HETE formation both in vitro and in vivo, while inhibiting epoxygenase activity 
with an IC50 value of 50 M [115]. 
 
1.4.2 20-HETE Antagonists 
 
Several 20-HETE analogues have shown to antagonize 20-HETE activity in renal and 
cerebral arteries, such as 5-, 15-, 19-HETE and 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid 
(6(Z),15(Z)-20-HEDE) [40]. 2,5,8,11,14,17-hexaoxanonadecan-19-yl 20-hydroxyeicosa-
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6(Z),15(Z)-dienoate (20-SOLA) is a novel, water soluble, 20-HETE antagonist that has shown to 
be able to reduce blood pressure in cyp4a14 knockout mice [116].  
 
Table 1. Summary of 20-HETE inhibitors 
Name Structure IC50 for 20-HETE 
formation in renal 
microsomes 
Type of 
inhibitor 
Reference 
SKF-525A 
 
Unknown Mechanism-
based 
[40, 100, 
117] 
17-ODYA 
 
<100 nM (rat) 
 
Mechanism-
based 
[99, 102, 
118] 
ABT  
 
M range Mechanism-
based 
[118, 119] 
DDMS  
 
2M (rat) Mechanism-
based, 
Reversible 
[106, 107] 
DBDD  
 
2M (rat) Reversible [106] 
DPMS 
 
31 M (rat) Unknown  [106] 
10-SUYS 
 
10.1±2.6 M (rat) Mechanism-
based 
[120, 121] 
HET0016  
 
8.9±2.7 nM (human) 
35.2±4.4 nM (rat) 
Unknown [99, 108] 
3-(4-n-
Butoxyphenyl
)pyrazole 
 
23±12 nM (human) Unknown [110] 
TS-011 
 
8.42 nM (human) 
9.19 nM (rat) 
Unknown  [79] 
Fluoxetine 
 
Unknown   Alter CYP4A 
expression 
[112, 122] 
Isoniazid 
 
Unknown  Alter CYP4A 
expression 
[113, 114] 
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Resveratrol 
 
3 M (human liver 
microsomes) 
Time-dependent 
inhibition 
against 
CYP1A1, alter 
CYP4A 
expression 
[44, 123, 
124] 
Sesamin 
 
5.3 M (human) Unknown  [115] 
Sesamolin  
 
3.4 M (human) Unknown  [115] 
6(Z),15(Z)-
20-HEDE  
Unknown Antagonist [40] 
20-SOLA 
 
Unknown  Antagonist  [116] 
 
 
1.5 COMPUTATIONAL CHEMISTRY 
 
Protein structures can be ascertained by X-ray crystallography, NMR spectroscopy or electron 
microscopy. Protein crystallization is to crystallize protein to obtain its 3D structure, which can 
aid in in silico drug design. Crystallizing membrane-bound proteins has many barriers including: 
(1) extraction only takes place when detergents in presence due to the hydrophobicity of protein 
surfaces; (2) difficulty in purifying membrane proteins because of their instability once 
solubilized in detergents and (3) generating low yield from purified proteins to high-resolution 
structure [125]. In addition to the challenges of protein crystallization, the methods used for 
determining their structures also have their drawbacks. X-ray crystallography and NMR 
spectroscopy have disadvantages when membrane proteins are embedded in a lipid bilayer [126]. 
The only way to determine structure of membrane-bound protein in its membrane context is by 
Table 1 (continued) 
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using electron crystallography. This technique is not widely used because producing two-
dimensional crystals that diffract to high-resolution requires sufficient amount of stable and 
compatible membrane proteins [125].  
When a protein 3D structure is not available, homology modeling can help in 
constructing a 3D model of target protein and structure-based drug design [127]. Homology 
modeling, also known as comparative modeling, allows construction of 3D structure of target 
protein based on its amino acid sequence and templates of experimental 3D structures that are 
evolutionarily related to the target protein [128].  
The first step of homology modeling is to select the most appropriate template among 
available protein structures for target sequence. Templates can be found in databases like Protein 
Data Bank, CATH, MODBASE, SCOP and etc. [129]. BLAST server provides a comparison of 
the target sequence with a library of protein sequences and outputs a list of 3D protein structures 
based on the sequence identity [130]. The second step is to align the target sequence with the 
template, which is the basis for homology modeling. There are several methods that can achieve 
target-template alignment, including PSI-BLAST, SALIGN, SAM-T02 and etc. [129]. In some 
alignments, using multiple template structures and sequence information is beneficial [131]. For 
example, human CYP4F11 and CYP4F3A were aligned using mammalian CYP2C5 bound to 3-
dimethylsulfaphenazole, CYPBM3 (2HPD), CYPterp (1CPT), CYPcam (2CPP), and CYPeryF 
(1OXA) as structural templates [132]. If the sequence homology between target protein and 
protein template is larger than 50%, then the template protein structure will be a general good 
model. However, if the homology drops to 20%, there will be large structural differences [133]. 
After the alignment of a target sequence with the template sequence, the next step is to build and 
refine the 3D structural model of the target protein. The model should include building of the 
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backbone of the protein, loops and side-chains [134]. Several programs can carry out model 
building. The SWISS-MODEL models by the rigid-body assembly method, where rigid bodies 
derived from the core of the aligned regions are used to construct a model [129, 135]. The 
SegMOD program employs modeling by segment matching, where atomic positions obtained 
from the alignment were used to find resembling segments [135, 136]. The third method is to 
model based on satisfaction of spatial restraint, which can be achieved by the MODELLER 
program [137]. The newest homology modeling method, artificial evolution, can be done by the 
NEST program, which employs the structural evolution from the template to the target protein 
[138, 139]. Homology modeling is a iterative process and needs model optimization which can 
be applied by molecular mechanics force field, molecular dynamics, Monte Carlo and genetic 
algorithm-based sampling [134]. Lastly, the homology model needs to be validated by 
determining if the model has the correct fold, similarity between the target and template 
sequences, stereochemistry of the model and model structure in the functional environment [134].  
Homology modeling can be used together with virtual screening to help identify novel 
compounds. Virtual screening enables identification of biologically active molecules that bind to 
the protein target [140]. When target information is available we can use structure-based virtual 
screening. In other cases, when this information is not available, ligand-based virtual screening 
can be used [141]. For example, two retinoic acid receptor (RAR) agonists with an IC50 value of 
50 nM were identified based on virtual screening from Available Chemicals Directory using a 
RAR-α model. One of the compounds displayed novel structural features that may assist in the 
development of novel ligands for cancer therapy [142]. Pharmacophore modeling is a major tool 
in ligand-based virtual screening in drug discovery. According to IUPAC, a pharmacophore 
model is an ensemble of steric and electronic features that is necessary to ensure the optimal 
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supramolecular interactions with a specific biological target and to trigger (or block) its 
biological response [143]. Pharmacophore modeling can be improved by ligand-based or 
structure-based methods [144]. For example, 22 structure-based and 3 ligand-based 
pharmacophore models identified 58 compounds that were potential sEH inhibitors. Among 48 
tested compounds, 19 were sEH inhibitors with IC50 < 10 μM, one was the most potent with an 
IC50 of 4.2 nM [145].   
Human CYP4 family consists of 13 isozymes [99]. There is an ester bond between the 
heme 5-methyl group and a glutamic acid, which is conserved in the CYP4 family [146]. The 
sequence and structure of CYP4F2 is closely related to other isoforms in the CYP4F subfamily. 
CYP4F2 and CYP4F3B have high similarity in their amino acid sequences; they have more than 
93% sequence identity [147]. CYP4F11 has 80.0% and 82.3% sequence identity with CYP4F2 
and CYP4F3, respectively [148]. Thus, predicting the 3D structure of CYP4F2 using homology 
modeling and virtual screening against compound libraries could assist in discovery of novel 
selective and potent enzyme inhibitors. 
CYP450-derived eicosanoids have a wide range of biological functions and the alteration 
of eicosanoid levels is associated with pathophysiological conditions in CA, SAH and ischemic 
stroke. Since 20-HETE is a potent microvascular vasoconstrictor that plays a role in CBF 
autoregulation and cerebralvascular tone, CYP4A and CYP4F subfamilies that are involved in 
20-HETE formation may be potential therapeutic targets in these diseases. Consequently, 
development of enzyme inhibitors that target the CYP4F2 isoform should be studied profoundly 
to aid in the study of vasoactive metabolites pathophysiological roles. The goal of this research 
project is to identify novel, potent, selective, metabolically stable 20-HETE formation inhibitors 
with improved solubility and better BBB permeability.   
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2.0 METHODS AND MATERIAL 
 
 
2.1 CHEMICALS AND REAGENTS 
 
Test compounds 1-19 were obtained from a proprietary library available to our laboratory; test 
compounds 21-26 were obtained via virtual screening from NCI database against a CYP4F2 
homology model. Stock standards of (±)5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-
DiHET), (±)8,9-dihydroxy-5Z,8Z,14Z-eicosatrienoic acid (8,9-DiHET), (±)11,12-dihydroxy-
5Z,8Z,14Z-eicosatrienoic acid (11,12-DiHET), (±)14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic 
acid (14,15-DiHET), (±)8(9)-epoxy-5Z,11Z,14Z-eicosatrienoic acid (8,9-EET), (±)11(12)-
epoxy-5Z,8Z,14Z-eicosatrienoic acid (11,12-EET), (±)14(15)-epoxy-5Z,8Z,11Z-eicosatrienoic 
acid (14,15-EET), 20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid (20-HETE), 20-hydroxy-
5Z,8Z,11Z,14Z-eicosatetraenoic-16,16,17,17,18,18-d6 acid (20-HETE-d6), 12S-hydroxy-
5Z,8Z,10E,14Z-eicosatetraenoic acid (12-HETE), 15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic 
acid (15-HETE) and arachidonic acid (peroxide free) were purchased from Cayman Chemical 
Company (Ann Arbor, MI). Spectrophotometric grade dimethyl sulfoxide (DMSO) was 
purchased from Sigma-Aldrich (Milwaukee WI), high purity methanol (MeOH), ethyl ether and 
acetic acid and other solvents were purchased from Fisher Scientific (Pittsburgh, PA). NADPH, 
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(±)-Metoprolol (+)-tartrate and (±)-verapamil hydrochloride was purchased from Sigma-Aldrich 
(St. Louis, MO). Warfarin was a kind gift from Dr. Thomas D. Nolin’s lab. Human liver 
microsome (HLM) was purchased from CellzDirect (Carlsbad, CA). Rat liver microsomes (RLM) 
and recombinant CYP4F2 (rCYP4F2) were purchased from Seikisui Xenotech (Lenexa, KS). Rat 
kidney tissue was prepared by homogenization from male Sprague Dawley rats. RKM was 
prepared from differential centrifugation in a Beckman Coulter Optima XL-100K ultracentrifuge 
(Beckman Coulter, Fullerton, CA). Total protein concentration was determined by Lowry protein 
assay.  
 
 
2.2 MICROSOMAL INCUBATION ASSAY 
 
2.2.1 AA Microsomal Incubation 
 
To screen the inhibitory effects against 20-HETE formation, compounds were tested in four 
different types of microsomes, including HLM, RLM, RKM or rCYP4F2. Compounds were 
dissolved in either 100% methanol or 100% DMSO to yield 10 mM stock solutions. Microsome 
incubation conditions were previously optimized. Microsomal incubations contained HLM, 
RLM, RKM (300 μg/ml) or rCYP4F2 (25 pmol/ml), AA (100 μM), NADPH (1 mM) and test 
compounds with various concentrations (50 nM to 2500 nM) in a 1 ml total volume in 
microsomal incubation buffer (0.12 M potassium phosphate buffer containing 5mM magnesium 
chloride). Each compound had three replications (n=3). Vehicle group was used as control to 
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calculate percentage of eicosanoids formation rate. HET0016 (250 nM) was used as positive 
control. Incubates without NADPH group served as the negative control.  
Reaction was started by adding NADPH to the incubates and was carried out at 37°C in a 
shaking water bath for 20 min. Reaction was stopped by placing tubes on ice, followed by adding 
12.5 μl 20-HETE-d6 as internal standard to each sample. Microsomal incubations were extracted 
with 3 ml ethyl ether twice, dried down under nitrogen gas and reconstituted in 125 μl 80:20 
methanol: deionized H2O for analysis. 20-HETE formation was quantified using a validated 
UPLC-MS/MS assay and normalized by vehicle group [70]. Other eicosanoids including 15-, 12-
HETEs, 8,9-, 11,12-, 14,15-EETs, and 5,6-, 8,9-, 11,12-, 14,15-DiHETs were monitored 
simultaneously.  
 
2.2.2 Chromatographic Analysis of CYP Eicosanoids 
 
An Acquity ultra performance LC autosampler (Waters, Milford, MA) was used to separate 
HETEs, EETs and DiHETs on a UPLC BEH C18, 1.7 μm (2.1 × 100 mm) reversed-phase 
column (Waters, Milford, MA) protected by a guard column (2.1 × 5 mm; Waters, Milford, MA) 
of the same packing material. Column temperature was maintained at 55° C. Mobile phases 
consisted of 0.005% acetic acid, 5% acetonitrile in deionized water (A) and 0.005% acetic acid 
in acetonitrile (B). The flow rate for mobile phases is 0.5 ml/min. The initial mixture of mobile 
phase was 65:35 of A and B. Mobile phase B increased at 0.4 minutes after injection from 35% 
to 70% in a linear gradient over 4 minutes, and again increased to 95% over 0.5 minutes where it 
remained for 0.3 minutes. This was followed by a linear return to initial conditions over 0.1 
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minutes with a 1.5 minute pre-equilibration period prior to the next sample run. Total run time 
was 6.4 minutes for each injection. Injection volumes were 7.5μl. 
Mass spectrometric analysis was carried out using a TSQ Quantum Ultra (Thermo Fisher 
Scientific, San Jose, CA) triple quadrupole mass spectrometer using heated electrospray 
ionization (HESI). Mass spectrometer was operated in negative selective reaction monitoring 
(SRM) mode with unit resolutions at both Q1 and Q3 set at 0.70 Da full width at half maximum. 
Scan time was set at 0.01 s and collision gas pressure was 1.3 mTorr. Quantitation of HETEs, 
EETs, and DiHETs by SRM was performed by monitoring their m/z transitions. Analytical data 
was acquired and analyzed using Xcaliber 3.0 data system (ThermoFinnigan, San Jose, CA). 
 
 
2.3 MICROSOMAL STABILITY ASSAY 
 
2.3.1 Compounds Microsomal Stability Assay 
 
Microsomal incubates contained HLM (500 μg/ml), test compounds (1 μM) and NADPH (1.3 
mM) in a 1 ml total volume of microsomal incubation buffer (0.12 M potassium phosphate 
buffer containing 5mM magnesium chloride). Each compound had three replications (n=3).  
Reaction was started by adding NADPH to the incubates and was carried out at 37°C in a 
shaking water bath for 60 min. At 0, 15, 30, 45, 60 min, a 50 μl aliquot of incubates was taken 
out and reaction was stopped by adding aliquot into 200 μl ice-cold acetonitrile. After 
centrifugation at 14000×g for 5 min, 200 μl supernatant was taken out for UPLC-MS/MS 
analysis. Values at 0 min were used as corresponding control for test compounds. Varapamil, 
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metoprolol, and warfarin, categorized as fast, moderate and slow metabolism, were used as 
positive control. Incubates without NADPH group served as negative control. 
 
2.3.2 Chromatographic Analysis Of Compounds 
 
Compounds were separated using the same instrument on a UPLC BEH C18, 1.7 μm (2.1 × 100 
mm) reversed-phase column (Waters, Milford, MA). Column temperature was maintained at 
50°C. Mobile phases consisted of 0.1% formic acid in deionized water (A) and acetonitrile (B) 
with a flow rate of 0.25 ml/min. The initial mixture of mobile phase was 80:20 of A and B. 
Mobile phase B increased from 20% to 95% at 0.5 minutes after injection in a linear gradient 
over 3 minutes and maintained for 0.5 minutes. This was followed by a linear return to initial 
conditions over 1.5 minutes. Total run time per sample was 5 minutes and all injection volumes 
were 7.5μl. 
Mass spectrometric analysis was performed using a TSQ Quantum Ultra (Thermo Fisher 
Scientific, San Jose, CA) triple quadrupole mass spectrometer coupled with heated electrospray 
ionization (HESI) operated in positive selective reaction monitoring (SRM) mode with unit 
resolutions at both Q1 and Q3 set at 0.70 full width at half maximum. Quantitation by SRM 
analysis on compounds was performed by monitoring their m/z transitions. Scan time was set at 
0.01 s and collision gas pressure was set at 1.2 mTorr. Analytical data was acquired and analyzed 
using Xcaliber 3.0  data system (ThermoFinnigan, San Jose, CA). 
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2.3 STATISTICAL ANALYSIS 
 
Data were analyzed with SPSS Statistics 23.0. Data were presented as mean ± std of the percent 
of vehicle control. One-way ANOVA was carried out and corrected with Bonferroni as post-hoc 
test when comparing remaining 20-HETE between test compound group and vehicle group. 
Values that are statistically significant are designated by asterisks (*, p < 0.05). 
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3.0 RESULTS 
 
 
3.1 COMPOUNDS 1-15 INHIBITORY EFFECT AGAINST 20-HETE FORMATION IN 
HLM, RLM, RKM AND rCYP4F2 
 
Compounds 1-15 were obtained from a proprietary library that’s available to our laboratory. 
HET0016 and 15 compounds were dissolved in methanol to yield 10 mM stock concentrations. 
Final concentrations of all the compounds in microsomal incubation buffer were 250 nM. HLM, 
RLM, RKM, and rCYP4F2 all produced 20-HETE only when incubated with AA in the presence 
of NADPH. HET0016, used as a positive control, completely knocked down 20-HETE formation 
in rCYP4F2, HLM, RLM and RKM by 92.21±2.72%, 98.3±0.37%, 90.49±2.60% and 
97.42±9.54%, respectively. At 250 nM, compared with the no compound group, compound 3 and 
10 significantly inhibited 20-HETE formation by 51.60±3.32% and 53.62±5.93% in rCYP4F2. 
Compounds 3, 7, 10 inhibited 20-HETE formation by 21.00±6.60%, 26.86±6.73% and 
30.45±3.15% in HLM, respectively, without statistical significance. Compounds 3, 7, 10 didn’t 
show comparable inhibition effects in RLM or RKM as in rCYP4F2 or HLM. Interestingly, 
compound 14 and 15 only significantly decreased 20-HETE formation by 32.55±0.83% and 
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40.69±4.52% in RKM but not in HLM or RLM (Figure 2). Table 2 lists inhibition of all 15 
compounds against 20-HETE in percent of control in four different microsomes.  
 
 
Figure 2. Compounds 1-15 inhibition against 20-HETE formation in four different 
microsomes 
 
Table 2. Compounds 1-15 inhibition against 20-HETE formation in percent of control 
Name rCYP4F2 HLM RLM RKM 
No compound 100±15.7% 100±7.08% 100±10.4% 100±7.96% 
No NADPH ND 0.03±0.04% ND 0.73±1.46% 
HET0016 7.79±2.72% 1.70±0.37% 9.51±2.60% 2.58±0.54% 
Compound 1 61.6±18.8% 116±8.29% 118±5.77% 202±20.0% 
Compound 2  59.1±10.9% 102±16.3% 96.9±5.71% 206±28.9% 
Compound 3 48.4±3.32%* 79.0±6.60% 98.0±6.89% 92.4±3.55% 
Compound 4 89.5±9.18% 105±13.4% 131±7.89% 110±16.1% 
Compound 5 90.1±5.70% 88.3±13.4% 112±5.59% 76.5±13.7% 
Compound 6 91.2±4.61% 100±5.98% 110±10.4% 92.2±2.35% 
Compound 7 94.5±12.0% 73.1±6.73% 121±1.41% 121±6.09% 
Compound 8 112±10.4% 102±13.1% 109±5.16% 108±6.14% 
Compound 9 96.2±12.9% 85.1±2.24% 95.7±13.0% 92.8±4.89% 
Compound 10 46.4±5.93%* 69.6±3.15% 86.5±1.92% 101±10.1% 
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Compound 11 85.6±13.9% 116±5.24% 100±4.33% 102±5.49% 
Compound 12 129±13.9% 87.9±2.07% 101±3.8% 100±5.88% 
Compound 13 249±23.9% 145±18.9% 103±10.1% 81.1±4.80% 
Compound 14 157±23.5% 117±5.10% 97.8±1.06% 67.5±0.83%* 
Compound 15  108±5.77% 108±4.70% 91.9±2.37% 59.3±4.52%* 
 
Based on the result in HLM, compounds 3, 7, and 10 were selected to conduct microsomal 
incubations in HLM with different concentrations. Methanol was used as vehicle control; it didn’t 
inhibit 20-HETE formation at 1% (v/v). Compounds 3, 7 and 10 all exhibited dose-dependent 
inhibition against 20-HETE formation in HLM (Figure 3). As concentration increased from 250 
nM to 1000 nM to 2500 nM, compound 3 showed an increase in percent of inhibition from 
7.17±9.28% to 20.32±6.53% to 31.09±2.14%. Compound 7 decreased 20-HETE formation by 
35.99±2.90%, 59.43±1.25% and 75.40±0.42% at the three different concentrations. Compound 10 
showed a similar trend with 31.59±3.00%, 62.68±1.45% and 76.05±5.45% at the three 
concentrations. After several repeat of the experiment, compound 10 consistently showed the best 
inhibition effect among all the compounds in HLM and good inhibition effect in rCYP4F2 and 
RLM. Based on these results, compound 10 could be a potential lead compound. 
 
Table 2 (continued) 
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Figure 3. Compounds 3, 7, and 10 dose-dependent inhibition against 20-HETE formation in 
HLM 
 
 
3.2 COMPOUNDS 21-26 INHIBITORY EFFECT AGAINST 20-HETE FORMATION IN 
HLM, RLM, RKM AND rCYP4F2 
 
Compounds 21 to 26 were selected from virtual screening and tested in four different types of 
microsomes for comparison with HET0016. Compounds were dissolved either in methanol or 
DMSO to yield a 10 mM stock solution. Final concentrations of test compounds and HET0016 
were 2500 nM and 250 nM, respectively, in microsomal incubations. Methanol and DMSO were 
used as vehicle control for compounds dissolved in each solution. HLM, RLM, RKM and 
rCYP4F2 all produced 20-HETE in a NADPH-dependent manner. HET0016 inhibited 20-HETE 
formation profoundly in all four types of microsomes at 250 nM. At 2500 nM, compound 24 
significantly reduced 20-HETE formation by 12.82±2.26% in RLM. Compound 25 significantly 
inhibited 20-HETE formation in both rCYP4F2 and HLM but not in RLM or RKM. It decreased 
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20-HETE by 34.25±1.39% and 16.90±2.54% in rCYP4F2 and HLM, respectively. Compound 26 
reduced 20-HETE formation by 65.16±5.13%, 77.94±0.73%, 12.94±4.71% and 24.84±4.26% in 
rCYP4F2, HLM, RLM and RKM, respectively, with a lesser extent of inhibitory effect in RLM 
and RKM (Figure 4). Table 3 lists the remaining 20-HETE in percentage of control for six 
compounds in four types of microsomes.   
 
 
Figure 4. Compounds 21-26 inhibitory effect against 20-HETE formation in four different 
microsomes 
 
Table 3. Compounds 21-26 inhibition against 20-HETE formation in percent of control 
Name rCYP4F2 HLM RLM RKM 
No compound 140±10.8% 117±4.51% 103±5.46% 115±4.40% 
MeOH 100±7.56% 100±8.08% 100±4.04% 100±4.19% 
DMSO 100±3.23% 100±0.42% 100±2.41% 100±6.80% 
No NADPH 1.47% 0.22±0.09% 0.19±0.10% 0.17±0.21% 
HET0016 5.43±0.88% 2.39±0.52% 10.2±2.04% 3.34±0.42% 
Compound 21 124±7.79% 116±3.63% 109±8.50% 90.0±5.05% 
Compound 22 115±1.78% 108±10.0% 96.5±2.44% 93.9±5.03% 
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Compound 23 110±20.3% 79.0±6.60% 98.7±5.24% 113±4.12% 
Compound 24 113±16.3% 87.5±5.80% 87.2±2.26%* 95.6±3.78% 
Compound 25 65.8±1.39%* 83.1±2.54%* 115±3.97% 104±2.53% 
Compound 26 34.8±5.14%* 22.1±0.73%* 87.1±4.71% 75.2±4.26% 
 
Based on the previous 20-HETE inhibitory results in rCYP4F2 and HLM, compounds 25 
and 26 were selected for further analysis in HLM at 250 nM, 1000 nM and 2500 nM. 
Compounds 25 and 26 both showed a dose-dependent inhibitory effect against 20-HETE 
formation. As concentration increased, remaining 20-HETE was 109.54±4.61%, 90.74±7.74% 
and 74.09±5.38% when treated with compound 25. Compound 26 decreased 20-HETE formation 
by 45.21±10.81%, 62.57±4.67% and 73.87±0.83%, confirming that it could be a potential 
CYP4F2 enzyme inhibitor (Figure 5). Collectively, the initial screening in four different types of 
microsomes and dose-dependent inhibition results indicated that compound 10 and compound 26 
could serve as lead compounds for optimization. 
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Figure 5. Compounds 25 and 26 dose-dependent inhibition against 20-HETE formation in 
HLM 
 
 
3.3 COMPOUNDS 16-19 INHIBITORY EFFECT AGAINST 20-HETE FORMATION IN 
HLM, RLM, RKM AND rCYP4F2 
 
Compounds 16, 17, 18, and 19 were dissolved in DMSO to yield 10 mM stock concentrations. 
The final concentrations of all test compounds in the microsomal incubate was 2500 nM. HLM, 
RLM, RKM and rCYP4F2 all produced 20-HETE only in the presence of NADPH when 
incubated with AA. HET0016 completely blocked 20-HETE formation at 250 nM in rCYP4F2, 
HLM, RLM and RKM by 95.62±0.90%, 96.96±1.51%, 86.39±0.21% and 97.33±0.04%, 
respectively. At 2500 nM, compared with the corresponding vehicle group, compounds 18 and 
19 significantly inhibited 20-HETE formation in all four microsomes. Compounds 18/19 
inhibited 20-HETE formation by 93.96±0.32%/95.62±0.29%, 90.18±1.56%/91.40±1.34%, 
69.54±2.06%/70.52±1.60%, and 46.95±1.02%/27.82±1.72% in rCYP4F2, HLM, RLM and 
RKM, respectively. Compound 17 significantly inhibited 20-HETE formation by 82.43±2.53%, 
72.49±6.42%, 41.95±0.83% in rCYP4F2, HLM and RKM, except RLM (Figure 6). Table 4 lists 
percent of control of compounds 16-19 in four different microsomes.  
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Figure 6. Compounds 16-19 inhibitory effect against 20-HETE formation in four different 
microsomes 
 
Table 4. Compounds 16-19 inhibition against 20-HETE formation in percent of control 
Name rCYP4F2 HLM RLM RKM 
No compound 119±3.80% 119±14.5% 96.3±6.46% 110±1.97% 
DMSO 100±1.14% 100±9.94% 100±3.89% 100±3.76% 
No NADPH ND 0.21% 0.06% 0.24% 
HET0016 4.38±0.90% 3.05±1.51% 13.6±0.21% 2.68±0.04% 
Compound 16 109±16.4% 131±8.15% 115±11.3% 135±6.77% 
Compound 17 17.6±2.53%* 27.5±6.42%* 83.9±1.86% 58.0±0.83%* 
Compound 18 6.04±0.32%* 9.82±1.56%* 30.5±2.06%* 53.1±1.02%* 
Compound 19 4.38±0.29%* 8.60±1.34%* 29.5±1.60%* 52.2±1.72%* 
 
Compound 18 and 19 both dose-dependently inhibited 20-HETE formation in HLM 
(Figure 7A). As the concentration of these compounds increased from 25 nM to 100 nM to 250 
nM, the inhibitory effect also increased. Compound 18 increased inhibition from 13.09±1.12% to 
34.12±0.81% to 51.79±1.45%, while compound 19 saw inhibition from 13.76±1.64% to 
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36.24±3.24% to 55.68±1.21%, respectively. Based on thees results, we could infer that the IC50 
value of compound 18/19 is less than 250 nM in HLM. Compound 18, 19 showed even better 
inhibitory effects against 20-HETE formation in rCYP4F2. Compound 18, 19 inhibited 20-
HETE from 19.76±4.92% to 59.14±2.56% to 78.06±2.34% and 27.60±7.06% to 63.62±7.02% to 
81.28±2.00%, respectively. IC50 values of these compounds were less than 100 nM in rCYP4F2 
(Figure 7B). As Figure 7 shows, compound 18 and 19 had improved inhibitory effect against 20-
HETE formation compared with compound 10 or compound 26 at 250 nM.  
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Figure 7. Compounds 18 and 19 dose-dependent inhibition against 20-HETE formation in 
HLM (A) and rCYP4F2 (B).   
 
 
3.4 INHIBITORY EFFECT AGAINST EPOXYGENASE PATHWAY 
 
As discussed in the introduction section, CYP450 epoxygenase pathway is responsible for EETs 
formation. EETs are vasodilators that have neuroprotective effect. Thus, 20-HETE as well as 
8,9-, 11,12-, 14,15-EET and 5,6-, 8,9-, 11,12-, 14,15-DiHETs were monitored by UPLC-MS/MS 
simultaneously. Epoxygenase activity is reported by the sum of EETs and DiHETs as presented 
by percentage of control. In HLM, compound 10 (Figure 8A) inhibited 20-HETE formation in a 
dose-dependent manner, without inhibiting EETs or DiHETs formation. Compound 19 showed 
more potent inhibitory effect against 20-HETE formation, without inhibiting epoxygenase 
activity at 2500 nM (Figure 8B). Compound 26 (Figure 8C) showed 10-30% reduction in 
epoxygenase activity as concentration increased from 250 nM to 2500 nM. These data suggest 
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that compound 10 and compound 19 are potent 20-HETE formation inhibitors with IC50 values 
in nanomolar range with good hydroxylase selectivity, where they didn’t inhibit epoxygenase 
activity even at 2500 nM in HLM. 
 
 
Figure 8. Compound 10 (A), compound 19 (B) and compound 26 (C) selectivity data in 
HLM.  
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3.5 MICROSOMAL STABILITY PROFILE OF COMPOUNDS 
 
In early drug discovery process, compounds cannot be administered to human directly. In order 
to predict pharmacokinetic parameters like intrinsic clearance, in vitro systems are used. As 
compounds 10, 19, and 26 are promising as leads, we examined the metabolic stability of 
compounds 10, 19, and 26 in HLM. According to Nakamura et al., one pyrazole derivative of 
HET0016, 3-(4-n-Butoxyphenyl) pyrazole, had better solubility, stability under acidic 
environment and was also a selective potent 20-HETE inhibitor. 3-(4-n-butoxyphenyl)pyrazole 
was used as control since it already showed improved physicochemical properties compared with 
HET0016. Compounds 10, 19, 26 and 3-(4-n-butoxyphenyl)pyrazole were incubated in HLM 
during a 60-minute incubation time. 3-(4-n-butoxyphenyl)pyrazole had 35.08±5.66% remaining 
compound at the 30 min time point (Figure 9). Compared with 3-(4-n-butoxyphenyl)pyrazole, 
compound 26 was quickly metabolized with 3.50±0.75% remaining parent compound in 
incubates at 30 min. Compound 10 and compound 19 were slowly metabolized, with 
91.36±11.01% and 100.40±1.73% remaining compound in HLM, respectively. These data 
suggest that our compounds 10 and 19 are more stable in in vitro human liver microsomal 
incubates and have better intrinsic clearance than their comparator and compound 26.  
Based on the results above, we will prioritize compound 10 as our lead compound to 
work with, as it has potent inhibition effect against 20-HETE and better stability compared with 
3-(4-n-butoxyphenyl)pyrazole.  
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Figure 9. Microsomal stability profile of compound 10, 19, 26 and 3-(4-n-
Butoxyphenyl)pyrazole 
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4.0 DISCUSSION 
 
In this study, we identified three compounds 10, 19, and 26 as selective potent 20-HETE 
inhibitors that may serve as lead compounds for optimization by testing them in rCYP4F2, HLM, 
RLM, and RKM, together with stability assays.. 
 
 
4.1 INTERSPECIES DIFFERENCE 
 
In order to examine the inhibition effect between different species and confirm inhibition 
specificity towards CYP4F2 isoform, rCYP4F2, HLM, RLM, and RKM were used as screening 
systems. Mean 20-HETE formation rate in HLM, RLM, RKM, rCYP4F2 without compound was 
570.64, 629.81, 351.99 pmol/min/mg P450 and 0.52 pmol/min/pmol P450, respectively. 20-
HETE was the most abundant metabolite in rCYP4F2, HLM, RLM and RKM. This is in 
consistent with the finding that ω-hydroxylation accounts for 50-75% of AA metabolism in 
humans, and 13-28% are EETs [149].  
We observed interspecies difference in 20-HETE inhibition with test compounds. For 
example, compounds 10, 18 and 19 inhibited 20-HETE in rCYP4F2 and HLM, but to a lesser 
extent in RLM and RKM. Compounds 14 and 15 only inhibited 20-HETE formation in RKM. 
Possible explanations include: (1) isoforms that are responsible for generating 20-HETE in 
humans and rats are different. CYP4A11 and 4F2 are major isoforms for 20-HETE formation in 
humans, while CYP4A1, 4A2 in rats. (2) Even if isoforms are same in different species, the 
difference in primary sequence of CYP protein will result in different substrate specificity. (3) 
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The level of CYP isoforms expression may be different in species. (4) There may be distinct 
catalytic activity for one substrate in different species as well [150]. For new drug development, 
isoform composition, expression and catalytic activity need to be considered when extrapolating 
preclinical data to humans.  
 
 
4.2 EFFECT OF ORGANIC SOLVENT ON METABOLIC ACTIVITY 
 
In the initial screening for compounds 1-15, data were obtained by normalizing 20-HETE 
formation rate to no compound group. Compounds 3, 7, and 10 were selected and their inhibition 
data were then confirmed by normalizing formation rate by vehicle group in dose-dependent 
inhibition experiment. We observed that as methanol concentration increased from 0.25%, 0.5%, 
0.75%, 1%, 2%, to 5%, there was a dose-dependent reduction in rCYP4F2 catalytic activity. 
Concentration at 1% for methanol or 0.5%: 0.5% methanol: DMSO did not significantly reduce 
20-HETE formation. Methanol Concentration higher than 2% significantly reduced rCYP4F2 
catalytic activity. The vehicle group (1% methanol or 0.5%: 0.5% methanol: DMSO) was used 
as control in subsequent analyses for all four types of microsomes. Chauret et al. evaluated 
methanol, DMSO, ACN on several HLM isoforms catalytic activity. Various isoforms were not 
affected by 1% methanol except for CYP2C8, 2C9, and 2E1 [151]. For CYP 2C8, 2C9, 2C19, 
2E1, and 3A4 isoforms, even 0.2% DMSO inhibited their catalytic activity [151]. The presence 
of organic solvent may affect certain isoform catalytic activity. This should be taken into account 
when dissolving compound for inhibition study or examining compound in vitro metabolic 
pathways.  
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4.3 INDUCTION IN 20-HETE FORMATION 
 
We observed compounds, such as compound 13, showed an induction in 20-HETE formation. 
One possible explanation is enzyme activation. It had been reported that 7,8-benzoflavone as a 
CYP3A4 substrate itself, activated CYP3A4-catalyzed phenanthrene metabolism [152]. Shou et 
al. found that 7,8-benzoflavone didn’t change Km of phenanthrene metabolism, while increasing 
the Vmax of phenanthrene metabolism and that phenanthrene didn’t increase Km of 7,8-
benzoflavone metabolism, while decreasing the Vmax, which indicated that more than one 
molecule could bind to CYP3A4 active sites simultaneously [152]. Subsequently, a two-substrate 
model was developed by the same laboratory, which could be used to explain phenanthrene/7,8- 
benzoflavone metabolism[153]. Phenanthrene and 7,8- benzoflavone serve as each other’s 
effector of metabolism. 7,8-benzoflavone stimulates phenanthrene metabolism by 15.7-fold, 
while phenanthrene is a partial inhibitor of 7,8-benzoflavone metabolism. In the presence of the 
other substrate, binding constants are relatively unaffected. These data suggested that 
phenanthrene and 7,8-benzoflavone couldn’t displace each other from the active site. In the 
presence of a certain compound, there is a possibility that AA still can bind to the active site of 
CYP4F2 or other isoforms that can convert AA, which may stimulate the generation 20-HETE. 
Compounds that showed an increase in 20-HETE formation need to undergo further 
experimental confirmation. Mechanisms of compounds inhibition towards CYP4F2 also need 
further elucidation.  
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4.4 ENDOGENOUS OR EXOGENOUS COMPOUNDS THAT SHARE CYP4F2 
METABOLISM PATHWAY 
 
To date, there have been several substrates of CYP4F2 being reported. CYP4F2 is responsible 
for ω–hydroxylation of endogenous substrates AA and leukotriene B4 (LTB4). CYP4A11 and 
4F2 exhibited 20-HETE formation rate of 15.6 and 6.8 nmol/min/nmol P450, while antibodies to 
CYP4F2 inhibited 20-HETE formation by 93.4% [47]. Leutotriene B4 is a derivative of AA, 
which can be converted to 20-hydroxyleukotriene B4 by CYP4F2 at a turnover rate of 392 
pmol/min/nmol P450 [154]. CYP4F2 is also an oxidase for vitamin K, which is associated with 
warfarin dosage. McDanold et al. showed that CYP4F2 V433M (rs2108622) allele have a 
reduced capacity to metabolize vitamin K1 in human liver microsomes [155]. This could be an 
explanation for high inter-individual variability in warfarin dosage. A meta-analysis that includes 
13 clinical studies showed that patients with CYP4F2 CT and TT genotypes require 10% and 21% 
higher warfarin doses [156].  
CYP4F2 also plays a role in metabolizing xenobiotics. Fingolimod is a FDA approved 
treatment for relapsing multiple sclerosis. Jin et al. reported that only recombinant human 
CYP4F2 and to some extent CYP4F3B produced fingolimod metabolites similar to those in 
HLM, and an antibody of CYP4F2 inhibited fingolimod metabolism completely in HLM [157]. 
Brincidofovir (CMX001) is an antiviral drug for treating cytomegalovirus, adenovirus, smallpox, 
and ebolavirus infections currently in Phase III clinical trials. Tippin et al. demonstrated that 
CYP4F2 is the major enzyme involved in CMX001 metabolism by the data that CMX001 
metabolism was inhibited by HET0016 and ketoconazole in both HLM and human rCYP4F2. 
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CYP4F2 is also responsible for ω–hydroxylation for tocopherol and tocotrienol. This is 
supported by the results that human rCYP4F2 oxidized tocopherol into its terminal hydroxylated 
and carboxylated metabolites, and 1 μM sesamin inhibited tocopherol metabolism in rCYP4F2, 
HLM, and RLM by more than 80% [158]. Vitamin E is composed of tocopherols and 
tocotrienols. Thus, CYP4F2 plays a role in regulating vitamin E metabolism. In insect cells that 
express wild type or polymorphic variants of the human CYP4F2, the W12G variant had two-
fold higher enzymatic activity towards tocopherols and tocotrienols, whereas the V433 variant 
showed one half of the enzymatic activity compared with wild type [159].  
The expression level of CYP4F2 may have effects when considering results in humans. 
Lasker’s group developed an antibody to quantify CYP4F2 expression in human liver and kidney, 
which is able to differentiate between CYP4F2, 4F3B, 4F11 and 4F12 [147]. They found 
CYP4F2 expression is highly variable (0-80.1 pmol/mg microsomal protein) in human liver 
microsome from 29 subjects pool with a mean of 18.2 ± 19.9 pmol/mg [147]. CYP4F2 has lower 
level and less variability in human kidney microsomes (n=10), ranging from 0 – 11.3 pmol/mg 
microsomal protein with a mean of 3.9 ± 3.8 pmol/mg [147]. Subsequently, the pie chart of 
human liver CYP450 pie chart was updated for CYP4F subfamily, CYP4F enzymes account for 
approximately 15% of total CYP450 enzymes in human liver [160].  
Thus, enzymatic inhibition of CYP4F2 may induce changes in endogenous or exogenous 
substrates metabolism. 20-HETE metabolism pathway needs to be further elucidated, as well as 
CYP4F2 polymorphism need to be considered to better predict potential interactions between 
substrates being metabolized by CYP4F2. 
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4.5 PHYSICOCHEMICAL PROPERTIES FOR DRUGGABLE COMPOUNDS 
 
In order to optimize compounds to increase potency and selectivity, Lipinski rule of fives (RO5) 
is used to evaluate druglikeness properties. RO5 include: (1) molecular weight ≤ 500, (2) 
LogP (the logarithm of the partition coefficient between water and 1-octanol) ≤ 5, (3) H-bond 
donors ≤ 5, (4) H-bond acceptors ≤ 10 [161]. When aiming to produce neuroprotective effects in 
the brain, compounds with molecular weight ≤ 450, LogP values ranging between 1.5-2.7, 
heteroatoms capable of hydrogen bonding (O+N) ≤ 5, PSA within 60-70Å, rotatable bonds ≤ 5, 
and pKa around 7-8 showed good BBB penetration [162].   
Physicochemical characteristics of compounds need to be considered during optimization 
of lead compound identified in our study. When advancing from preclinical to clinical studies, 
physicochemical properties, pharmacokinetic parameters including metabolic stability, metabolic 
liability, permeability and protein binding as well as patients pathophysiological need to be 
accounted to select the most appropriate drug candidate.  
 
 
4.6 sEH INHIBITION OR 20-HETE INHIBITION 
 
20-HETE and sEH have been investigated as potential therapeutic targets for cerebral vascular 
diseases. Both 20-HETE inhibition and sEH inhibition or sEH gene deletion demonstrated 
positive neurological outcome. The major holdback for investigating 20-HETE pathogenesis role 
in human is lacking suitable druggable inhibitor. In 2005, TS-011 was in a phase I clinical trial in 
acute ischemic stroke patients. However, with no follow-up information provided, it is likely that 
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TS-011 failed in phase I clinical trial for some unknown reason. Sesamin is the other 20-HETE 
inhibitor that underwent clinical trials. Overweight men and postmenopausal women receiving 
sesame bar (providing 26.2 g of sesame seeds per day) had 28% reduction in plasma unesterified 
20-HETE levels and a 32% reduction in urinary excretion [115]. On the contrary, sEH inhibitors 
progressed further in clinical trials. AR9281, a sEH inhibitor, was in phase IIa clinical trials in 
pre-diabetic patients, but failed to show efficacy in early-stage hypertension. EC5026 is a novel 
sEH inhibitor that showed efficacy in diabetic neuropathic pain, and phase I clinical trial will be 
initiated to study safety profile of EC5026.  
20-HETE synthase inhibitors and 20-HETE receptor antagonists have their pros and cons. 
20-HETE synthase inhibitors works on the enzymes that form 20-HETE, such as CYP4A or 
CYP4F subfamilies. However, inhibiting the enzymes may lead to disruptions of metabolism  of 
other endogenous or exogenous compounds, like vitamin K. To date, there have been no explicit 
20-HETE receptors being reported, antagonists were designed based on the structure of 20-
HETE. 20-HETE antagonists compete with 20-HETE to bind with the receptor, thus leaves the 
substrates that metabolized by the enzymes unaffected. However, receptor antagonists inhibit 
effects of preformed 20-HETE if present in esterified lipids in the membrane, and we are not 
clear right now that if there are other ligands that work through that receptor or not. Further 
considerations and studies will be needed to elucidate the difference between this two strategies. 
sEH is a promising therapeutic target in cardiovasuclar diseases. Inhibiting sEH to 
increase EETs showed favorable outcomes in spontaneously hypertensive stroke-prone rats [163]. 
However, sEH gene deletion may result a shift in HETEs production. For example, while kidney 
homogenates from sEH gene deletion mice had lower DiHETs levels and higher EETs levels, 
20-HETE levels increased by four fold [164]. Plasma concentration of 9-, 11-, 15-, 19-HETE 
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was increased by two fold in sEH gene knockout mice [165]. This suggests that hydroxylase 
activity is increased in sEH gene knockout mice.  
Inhibition of 20-HETE provided beneficial effects in cardiovascular and cerebrovascular 
diseases. Reduction in 20-HETE formation improves CBF and neurological outcomes. Enzymes 
that metabolize AA also metabolize exogenous compounds. Inhibiting enzymes that are 
responsible for 20-HETE formation may lead to alterations of enzyme substrate levels. The role 
of 20-HETE is the basis that produces deleterious effects in diseases. Targeting 20-HETE 
formation is aiming at the origin that causes neurological deficits. In acute ischemic stroke 
patients, baseline 20-HETE level was positively associated with lesion size, but not EETs or 
DiHETs [89]. 20-HETE was also associated with functional indices including greater 
neurological impairment, reduced modified barthel index (MBI), and reduced cognitive function, 
while EETs or DiHETs had no association with functional indices. Further studies need to be 
carried out to compare the beneficial effects of two strategies, or testing if sEH inhibition plus 
20-HETE inhibition will have synergistic effects in cerebral vascular and cardiovascular diseases.   
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5.0 CONCLUSION 
To summarize, in the work we screened 26 compounds, compounds 10, 19, and 26 were 
potent 20-HETE formation inhibitors with an IC50 value in nano molar range. Compounds 10 
and 19 dose-dependently inhibited 20-HETE formation and showed good selectivity for 
hydroxylase pathway, they didn’t inhibit epoxygenase at 2500 nM. Compound 26 decreased 
epoxygenase activity for around 10-30%. Compounds 10 and 19 were metabolically stable in 
HLM though out a 60-minute incubation period, while compound 26 was quickly metabolized 
within 30 minutes. Thus, compound 10, 19, and 26 can serve as lead compounds for structure 
optimization, and we will prioritize with compound 10 and 19. 
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6.0 FUTURE DIRECTION 
 
Experiments need to be conducted to obtain IC50 values of lead compounds in order to 
confirm compounds inhibition potency. More selectivity evaluation of compound inhibition 
against other CYP isoforms will need to be done to provide evidence if compounds are selective 
to isoforms that only produce 20-HETE instead of other drug metabolizing CYP enzymes. More 
compounds will need to be experimentally tested in vitro in order to select a potential in vivo 
candidate. Also, lead compounds incubated in brain microsomes would give relevant information 
towards eicosanoids enzymatic formation in the brain. The ultimate goal at the current state is to 
screen and identify the compound that has the optimum physicochemical properties, including 
potency, solubility, selectivity, microsomal stability and ability to across BBB. CYP4F2 
homology model will be optimized based on the screening results at the same time to support 
compound design and virtual screening. 
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APPENDIX. ABBREVIATION 
 
4-PCO 4-phenylchalcone oxide 
10-SUYS 10-undecynyl sulfate 
17-ODYA  17-octadecynoic acid 
20-HETE 20-hydroxyeicosatetraernoic acid  
20-SOLA 2,5,8,11,14,17-hexaoxanonadecan-19-yl-20-hydroxyeicosa-6(Z),15(Z)-
dienoate 
AA Arachidonic acid 
ABT 1-aminobenzotriazole 
AHA American Heart Association 
ASA American Stroke Association 
aSAH Aneurysmal subarachnoid hemorrhage 
BBB Blood brain barrier 
CA Cardiac arrest  
CBF Cerebral blood flow 
CO Carbon monoxide  
COX Cyclooxygenase  
cPLA2 Cytosolic phospholipase A2 
CPP Cerebral perfusion pressure 
CPR Cardiopulmonary resuscitation 
CSF Cerebral spinal fluid 
CPP Cerebral perfusion pressure 
CYP Cytochrome P450 
DBDD 12-12-dibromododec-11-enoic acid 
DCI Delayed cerebral ischemia 
DDMS N-methylsulfonyl-12,12-dibromododec-11-enamide 
DiHET Dihydroxyeicosatrienoic acid  
DPMS N-methylsulfonyl-15,15-dibromopentadec-14-enamide 
EET Epoxyeicosatrienoic acid 
EBI Early brain injury 
eNOS Endothelial nitric oxide synthase 
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FDA Food and Drug Administration 
HET0016 N-hydroxy-N-(4-butyl-2-methylphenyl) formamidine 
ICP Intracranial pressure 
ICH Intracerebral hemorrhage 
LOX Lipoxygenase  
LTB4 Leukotriene B4 
MCAO Middle cerebral artery occlusion  
MS/MS Tandem mass spectrometry 
NADPH Nicotinamide adenine dinucleotide phosphate  
NO Nitric oxide 
PGF2α Prostaglandin F2α 
PGI2 Prostacyclin  
PPAR Peroxisome proliferator-activated receptor alpha 
PSA Polar surface area 
rt-PA Recombinant tissue-type plasminogen activator 
SAH Subarachnoid hemorrhage  
sEH Soluble epoxide hydrolase  
SKF-525A β-diethyl-aminoethyldiphenylpropylacetate 
SRM Selective reaction monitoring  
TIA Transient ischemic attack 
TS-011 N-(3-chloro-4-morpholin-4-yl) phenyl-N′-hydroxyimido formamide 
TXA2 Thromboxane A2 
TXB2 Thromboxane B2 
UPLC Ultra-performance liquid chromatography 
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